Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis

Rheumatoid arthritis

(2016) Josef S Smolen et al.   LANCET

FRI0164 Safety, Tolerability, And Functional Activity of ABT-122, A Dual TNF- and IL-17A–Targeted DVD-IG™, Following Single-Dose Administration in Healthy Subjects

(2015) H. Mansikka et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

(2015) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Abstract 1275: Chemotactic factors underlying tumor infiltration by immunocompetent cells in colorectal cancer

(2015) Eleonora Cremonesi et al.   CANCER RESEARCH

Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis

(2015) D. N. Hull et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate

(2015) K. Pavelka et al.   JOURNAL OF RHEUMATOLOGY

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   Arthritis & Rheumatology

T cell migration in rheumatoid arthritis

(2015) Mario Mellado   Frontiers in Immunology

How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?

(2014) Roy Fleischmann et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0521 Dual Neutralization of TNF and IL-17 with A Dvd-Ig Protein is Efficacious in Collagen Induced Arthritis

(2014) C. Cuff et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0303 Discovery and Characterization of Abt-122, an Anti-TNF/IL-17 Dvd-Ig™ Molecule as A Potential Therapeutic Candidate for Rheumatoid Arthritis

(2014) C.-M. Hsieh et al.   ANNALS OF THE RHEUMATIC DISEASES

Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity

(2014) Jason W. Griffith et al.   Annual Review of Immunology

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

(2014) Mark C. Genovese et al.   Arthritis & Rheumatology

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases

(2013) Alessandro Antonelli et al.   AUTOIMMUNITY REVIEWS

Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis

(2013) C Eriksson et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis

(2012) E. Choy   RHEUMATOLOGY

CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis

(2011) Teresina Laragione et al.   ARTHRITIS AND RHEUMATISM

Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial

(2011) Maria W. Greenwald et al.   ARTHRITIS AND RHEUMATISM

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

(2011) Der-Yuan Chen et al.   ARTHRITIS RESEARCH & THERAPY

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

CXCL 9 and CXCL 10 as Sensitive Markers of Disease Activity in Patients with Rheumatoid Arthritis

(2009) W. P. KUAN et al.   JOURNAL OF RHEUMATOLOGY

Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis

(2009) PA Klimiuk et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor

(2008) Inmaculada Rioja et al.   ARTHRITIS AND RHEUMATISM